Rapid Medical's TigerTrieve stent-retriever neuro thrombectomy system.
April 7, 2021 — Market research firm GlobalData's new report, Neurovascular Thrombectomy Devices (Neurology Devices), shows the U.S. thrombectomy device market is worth about $265 million in 2020 and is predicted to grow to $465 million by 2025. The data and analytics company said this this growth will be driven by an increase in thrombectomy procedures and the newly approved adjustable stent retriever device.
There are two types of devices for extracting stroke-causing clots in the arteries of the brain — stent retrievers and aspiration catheters. These devices can be used individually or in combination. While the clinical outcomes and revascularization rates is similar for both the device, used separately or in conjugation, the aspiration retriever is quicker and easier to operate and is therefore becoming more popular.
The U.S. Food and Drug Administration (FDA) recently approved Rapid Medical’s TigerTriever, the first adjustable stent retriever approved in the U.S. The approval followed promising results from the device's multi-center trial. The TigerTriever’s main advantage over current stent retrievers is that the diameter of the basket, where a clot is caught and extracted, can be adjusted via a slide on the handle of the device. This allows neuro interventional operators greater control over the procedure, increasing patient compatibility and potentially lowering the risk of clot fragmentation.
“Mechanical thrombectomy has become increasingly popular in recent years compared to managing stroke patients using medical managements, as early clinical studies suggest that it potentially leads to improved clinical outcomes," said Dominic Tong, medical devices analyst at GlobalData. "Stent retrievers aim to trap a clot within their basket, allowing the clots to be removed from the blood vessel, while aspiration catheters rely on suction to remove the clots."
Tong said any innovations that further increase the efficacy and safety of mechanical thrombectomy are welcome. With continual improvements, he said mechanical thrombectomy may eventually overtake medical management as the preferred treatment for some cases.
“Additionally, while the thrombectomy market has been relatively resilient through the COVID-19 pandemic, it still experienced a drop in revenue that was potentially due to increased hospital load making it harder for operations to happen within eight hours of symptom onset. As vaccines rollout and hospitals return to business as usual, Rapid Medical has an opportunity to capitalize on the rebounding market and capture more market share during this period of recovery,” Tong said.
Among the near thrombectomy companies mentioned in the report are:
• Cerenovus
• Medtronic plc
• phenox GmbH
• MicroVention Inc
• Stryker Neurovascular
• Imperative Care Inc
• Penumbra Inc
• Balt Extrusion SAS
• Acandis GmbH & Co KG
May 16, 2023 
